Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Mirko D’Onofrio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3229-9329; OpenAlex author ID A5023308842. Sources: OpenAlex.

Their work

Papers
37 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
106
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 4 papers · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 37

  1. Conspicuity and characterization of pre-selected hypodense hepatic lesions in pancreatic cancer patients: limited clinical value of dual-energy portal phase CT. Last author DOI 10.1007/s00261-026-05802-9↗
  2. Can Machine Learning Predict Metastatic Sites in Pancreatic Ductal Adenocarcinoma? A Radiomic Analysis. Last author DOI 10.1007/s10278-025-01627-y↗
  3. CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2026.102900↗
  4. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  5. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  6. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  7. Liver metastases in pancreatic ductal adenocarcinoma: a predictive model based on CT texture analysis. Last author DOI 10.1007/s11547-022-01548-8↗
  8. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Co-author DOI 10.1055/a-1178-0474↗
  9. Correlation between ADC Histogram-Derived Metrics and the Time to Metastases in Resectable Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers14246050↗
  10. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  11. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  12. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. Co-author DOI 10.1016/j.ultrasmedbio.2021.08.005↗
  13. Structured Reporting of Computed Tomography and Magnetic Resonance in the Staging of Pancreatic Adenocarcinoma: A Delphi Consensus Proposal. Co-author DOI 10.3390/diagnostics11112033↗
  14. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-020-02509-3↗
  15. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  16. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗
  17. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  18. Ablation treatments in unresectable pancreatic cancer. Co-author DOI 10.23736/s0026-4733.18.07881-1↗
  19. Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. Last author DOI 10.3390/cancers11020267↗
  20. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.0979↗
  21. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  22. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
  23. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Co-author DOI 10.21037/tgh.2018.10.05↗
  24. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Co-author DOI 10.1177/1533034616649292↗
  25. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Co-author DOI 10.1245/s10434-017-5885-4↗
  26. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. Co-author DOI 10.4103/eus.eus_67_17↗
  27. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer. Co-author DOI 10.1007/s13304-016-0385-9↗
  28. Percutaneous ablation of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i44.9661↗
  29. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.085↗
  30. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Co-author DOI 10.1159/000375323↗
  31. Contrast enhanced ultrasound with quantitative perfusion analysis for objective characterization of pancreatic ductal adenocarcinoma: A feasibility study. Co-author DOI 10.4329/wjr.v6.i3.31↗
  32. Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejrad.2012.09.023↗
  33. Comparison between CT and CEUS in the diagnosis of pancreatic adenocarcinoma. Co-author DOI 10.1055/s-0032-1325324↗
  34. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1016/j.amjsurg.2011.03.008↗
  35. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2012.05.017↗
  36. Clinicopathological features of adenosquamous pancreatic cancer. Co-author DOI 10.1007/s00423-010-0677-3↗
  37. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Co-author DOI 10.1245/s10434-011-1769-1↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Riccardo De Robertis · 17 shared papers, 2013–2026 · strength 2.38
  2. Roberto Salvia · 20 shared papers, 2015–2025 · strength 1.88
  3. Claudio Bassi · 22 shared papers, 2011–2025 · strength 1.73
  4. Giuseppe Malleo · 14 shared papers, 2011–2026 · strength 1.68
  5. Salvatore Paiella · 17 shared papers, 2015–2025 · strength 1.38
  6. Davide Melisi · 6 shared papers, 2018–2026 · strength 0.75
  7. Isabella M. Frigerio · 9 shared papers, 2015–2022 · strength 0.72
  8. Aldo Scarpa · 6 shared papers, 2018–2025 · strength 0.69
  9. Giovanni Butturini · 9 shared papers, 2011–2024 · strength 0.64
  10. Roberto Girelli · 8 shared papers, 2016–2022 · strength 0.61
  11. Flavio Spoto · 2 shared papers, 2026 · strength 0.60
  12. Michèle Milella · 4 shared papers, 2020–2026 · strength 0.59
  13. Alessandro Beleù · 4 shared papers, 2019–2022 · strength 0.51
  14. Simona Casalino · 3 shared papers, 2020–2026 · strength 0.51
  15. Giovanni Marchegiani · 6 shared papers, 2018–2024 · strength 0.50
  16. Stefano Francesco Crinò · 4 shared papers, 2018–2025 · strength 0.49
  17. Alessandro Esposito · 5 shared papers, 2018–2024 · strength 0.46
  18. Matteo De Pastena · 5 shared papers, 2018–2021 · strength 0.40
  19. Gabriella Lionetto · 3 shared papers, 2021–2025 · strength 0.37
  20. Alessandro Giardino · 5 shared papers, 2016–2021 · strength 0.36
  21. Vincenzo Corbo · 2 shared papers, 2025 · strength 0.33
  22. Claudio Luchini · 2 shared papers, 2024–2025 · strength 0.31
  23. Erica Secchettin · 4 shared papers, 2018–2021 · strength 0.30
  24. Valeria Merz · 3 shared papers, 2019–2024 · strength 0.29
  25. Paola Capelli · 5 shared papers, 2011–2020 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.